Jyong Biotech (MENS) vs Nkarta (NKTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Nkarta (NKTX) has outperformed Jyong Biotech (MENS) over the past year, losing 4.7% versus a loss of 95.9%. Nkarta is the larger company by market cap ($161.2 million vs $159.7 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MENS | NKTX |
|---|---|---|
| Share price | $2.10 | $2.25 |
| Market cap | $159.66M | $161.16M |
| 1-day change | 0.00% | +1.35% |
| YTD return | -46.84% | +21.62% |
| 1-year return | -95.89% | -4.66% |
| 5-year return | — | -87.73% |
| EPS (TTM) | $-0.06 | $-1.58 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $63.00 | $3.72 |
| 52-week low | $1.43 | $1.70 |
| Distance from 52-week high | -96.67% | -39.52% |
| Analyst consensus | — | strong_buy |
| Avg. price target upside | — | +381.33% |
| Average volume | 45.62K | 613.16K |
| Shares outstanding | 74.23M | 71.62M |
| Employees | 27 | 106 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NKTX has outperformed MENS by 91.2 percentage points over the past year.
About Jyong Biotech
MENS stock →Jyong Biotech Ltd., a science-driven biotechnology company, engages in the development and commercialization of plant-derived drugs for the treatment of urinary system diseases in the United States, the European Union, and Asia. It develops Botreso, for the treatment of benign prostate hyperplasia/lower urinary tract symptoms; PCP for treating prostate cancer; and interstitial cystitis (IC) for the treatment of IC/bladder pain syndrome.
Health Care · Biotechnology: Pharmaceutical Preparations · 27 employees
About Nkarta
NKTX stock →Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis.
Health Care · Biotechnology: Pharmaceutical Preparations · 106 employees
MENS vs NKTX FAQ
Which is bigger, Jyong Biotech or Nkarta?
Nkarta (NKTX) is larger, with a market capitalization of $161.16M compared with $159.66M for Jyong Biotech (MENS).
Which stock has performed better over the past year, MENS or NKTX?
NKTX returned -4.66% over the past 12 months, compared with -95.89% for MENS (price return, excluding dividends). Past performance does not predict future results.
Are Jyong Biotech and Nkarta in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.